Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00944554 · ClinicalTrials.gov registry record · Phase 4
Relapse Prevention With Varenicline
A Phase 4 study of Smoking Cessation and Substance-Related Disorders, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT00944554: Completed Phase 4 study of Smoking Cessation and Substance-Related Disorders, sponsored by Johns Hopkins University.
NCT00944554 is a Phase 4 study of Smoking Cessation and Substance-Related Disorders that has completed, run by Johns Hopkins University. The registered enrollment target is 104 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00944554, a Phase 4 study of Smoking Cessation and Substance-Related Disorders, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.
Primary Outcome
Number of days following the programmed lapse exposure until relapse to smoking occurred
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline
Study Locations (1)
Maryland
- Behavioral Pharmacology Research Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-05 |
| Phase | Phase 4 |
What the finished NCT00944554 record still lists
NCT00944554 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (78% lower).
The record links to 3 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00944554 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00944554 about?
NCT00944554 is a clinical study titled "Relapse Prevention With Varenicline". This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or pr...
What is the current status of trial NCT00944554?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 104 participants. The study started on 2008-10. Estimated completion is 2011-05.
What conditions does trial NCT00944554 study?
This clinical trial studies the following conditions: Smoking Cessation, Substance-Related Disorders, Recurrence.
What interventions are being tested in trial NCT00944554?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT00944554?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00944554 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00944554's enrollment target sits among peer trials
104 117th of 188 higher than 72 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
RECRUITING · Phase 4
-
The Options 2 Study
RECRUITING · Phase 4
-
Smoking Cessation Program in the Construction Sector
RECRUITING · Phase 4
-
The Avenues Study: Dual Use Cessation
RECRUITING · Phase 4
-
Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care
RECRUITING · Phase 4
-
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia